CliffBio
small molecule

GLEEVEC

IMATINIB MESYLATE

Loss of exclusivity—loss of exclusivity
CompanyNovartis →See this company's full patent-cliff portfolio

Drug detail

Brand nameGLEEVEC
Active ingredientIMATINIB MESYLATE
StrengthEQ 100MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalMay 2001
Marketing statusDISCN

More from Novartis

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.